Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover
โ Scribed by H. Y. Meltzer; M. Simonovic; V. S. Fang; G. A. Gudelsky
- Publisher
- Springer
- Year
- 1982
- Tongue
- English
- Weight
- 520 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
โฆ Synopsis
Buspirone, an effective antianxiety compound, produced a dose-dependent, relatively prolonged increase in rat plasma prolactin (PRL) levels. The stimulation of PRL secretion by buspirone was additive with the effect of e-methyl-p-tyrosine (AMPT) or y-butyrolactone. In vitro, buspirone itself had no effect on the release of PRL from rat pituitary glands but it blocked the inhibitory action of dopamine (DA). Buspirone also increased DA turnover in the striatum as measured by the AMPT-induced depletion of striatal DA levels. These results demonstrate the ability of buspirone to block pituitary and striatal DA receptors.
๐ SIMILAR VOLUMES
Stobadine (STB), a cardioprotective drug, was evaluated for its effect on the intensity and habituation of exploratory behaviour in open field testing and on the levels of striatal dopamine (DA), serotonin (5-HT) and their metabolites (3,4-dihydroxyphenylacetic acid, homovanillic acid, 5-hydroxyindo
Levels of monoamine metabolites in three different regions of the rat brain were determined following treatment with piracetam (0.5 and 5g/kg, i.p.). The concentration of prolactin in serum was also measured. Piracetam, at 5 g/kg, increased the levels of dihydroxyphenylacetic acid, homovanillic aci